StockUS listing USADAPYPINKHealthcareEarnings Deterioration

Adaptimmune Therapeutics plc(ADAPY) Stock Analysis | Healthcare

USD --+0.00%
Reward52Moderate
Risk77High
75%Data
Thin -261% profit margin · Revenue down 89% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 6.89M
Reward Ratingⓘ52 Moderate reward assessment · 75% data coverage
Bottom 50% of stocksView factors
Risk Ratingⓘ77 High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ADAPY to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Adaptimmune Therapeutics plc?

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

AI Brief Pro

The brief on Adaptimmune Therapeutics plc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Adaptimmune Therapeutics plc?

Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA (famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment of synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 6.89M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Elevated volatility implies higher downside and expectation risk.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (52)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta2.424
Insider Activity
12M windowNo data
No insider activity data available for this ticker.